(Q36832124)

16 August 2017

1 reference

title

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients (English)

1 reference

16 August 2017

1 reference

acute myeloid leukemia

1 reference

L Pagano

1

1 reference

16 August 2017

L Fianchi

2

1 reference

16 August 2017

M Caira

3

1 reference

16 August 2017

S Rutella

4

1 reference

16 August 2017

G Leone

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

25

1 reference

16 August 2017

page(s)

3679-3690

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210364

16 August 2017

exact match

0 references

cites work

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Veno-occlusive disease of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Treatment of relapsed and refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Expression of cell-surface antigens in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210364

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210364

1 reference

Dimensions Publication ID

16 August 2017

1006318040

0 references

1 reference